共 114 条
[1]
Khan MAB(2023)Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 Lancet 402 203-234
[2]
Hashim MJ(2020)Epidemiology of type 2 diabetes - global burden of disease and forecasted trends J Epidemiol Glob Health 10 107-111
[3]
King JK(2019)Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition Diabetes Res Clin Pract 157 110-117
[4]
Govender RD(2012)Trends in prevalence of diabetes in Asian countries World J Diabetes 3 1741-1748
[5]
Mustafa H(2011)Deriving ethnic-specific BMI cutoff points for assessing diabetes risk Diabetes Care 34 534-545
[6]
Al KJ(2022)Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial JAMA 327 1811-1824
[7]
Saeedi P(2021)Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Lancet 398 503-515
[8]
Petersohn I(2021)Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes N Engl J Med 385 583-598
[9]
Salpea P(2021)Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Lancet 398 143-155
[10]
Malanda B(2021)Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Lancet 398 623-633